Drug Trial Radar · NCT06507306
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
92
Actual
Start
Jun 3, 2024
Primary completion
Dec 31, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Kumquat Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that
Conditions
- Solid Tumor, Adult
Interventions
KQB198Drug
Oral KQB198
OsimertinibDrug
Oral Osimertinib
AmivantamabDrug
Subcutaneous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 1)Time frame: 28 Days
- Recommended Phase 2 Dose (RP2D) (Part 1)Time frame: up to 30 months
- Efficacy and Optimal Biologic Dose of study treatment, as measured by Objective Response Rate (ORR) (Parts 2 and 3)Time frame: up to 30 months
Locations
26 sites in 4 countries. Site status is shown where the registry gives one.
Sarah Cannon Research Institute at HealthONE
Denver, Colorado
Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona -
Orlando, Florida
Florida Cancer Specialists - Sarasota
Sarasota, Florida
Henry Ford Health System
Detroit, Michigan
David H. Koch Center for Cancer Center at Memorial Sloan Kettering Cancer Center
Long Island City, New York
The Lindner Center for Research and Education at The Christ Hospital
Cincinnati, Ohio
Sarah Cannon and HCA Research Institute
Nashville, Tennessee
New Experimental Therapeutics of San Antonio - NEXT Oncology
San Antonio, Texas
New Experimental Therapeutics of Virginia - NEXT Oncology
Fairfax, Virginia
Institut Paoli-Calmettes
Marseille, Bouches-du-Rhône, France
Institut de Cancerologie de l'Ouest - site St-Herblain
Saint-Herblain, Loire-Atlantique, France
CHU Bordeaux - Hopital Saint-Andre
Bordeaux, Nouvelle-Aquitane, France
IUCT-Oncopole
Toulouse, Occitaine, France
CHU de Nantes - Hopital Nord Laennec
Nantes, Pays de la Loire Region, France
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Naples, Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, Lazio, Italy
New Experimental Therapeutics (NEXT) Oncology Barcelona
Barcelona, Spain
South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos
Barcelona, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
Madrid, Spain
New Experimental Therapeutics (NEXT) Oncology Madrid - Hospital Quironsalud Madrid
Madrid, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
Madrid, Spain
Hospital Quirónsalud Málaga
Málaga, Spain
Clinica Universidad de Navarra - Pamplona
Pamplona, Spain
Hospital Universitari Quiron Dexeus Barcelona
Barcelona, Catalonia, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Catalonia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.